GLP-2

also known as: Glucagon-Like Peptide 2

GLP-1's sibling hormone — a potent intestinal growth factor that drives gut epithelial repair, and the native molecule behind teduglutide (Gattex).

A 33-amino-acid gut hormone co-released with GLP-1 from the same proglucagon precursor, uniquely trophic to intestinal epithelium and the basis for teduglutide therapy in short bowel syndrome.

Mechanism of action

Binds the GLP-2 receptor on intestinal subepithelial myofibroblasts, triggering release of IGF-1, KGF, and EGF, which collectively stimulate crypt cell proliferation, inhibit apoptosis, and increase villus height, crypt depth, and mucosal blood flow.

Primary uses

Intestinal adaptation and repair research
Short bowel syndrome (via teduglutide analog)
Intestinal failure research
GI mucosal biology studies

Typical dosing

research infusion protocols (intravenous / subcutaneous)

Not used therapeutically in native form. Teduglutide is dosed at 0.05 mg/kg/day SC.

Regulatory status

Native GLP-2 not approved. Its DPP-4-resistant analog teduglutide (Gattex/Revestive) is FDA-approved for short bowel syndrome.

References

[review] Drucker DJ, et al. "Glucagon-like peptide 2." J Clin Endocrinol Metab, 2001;86:1759-1764.

Related peptides

Teduglutide

FDA-approved GLP-2 analog (Gattex/Revestive, 2012) for short-bowel syndrome — the first disease-modifying treatment for SBS, reducing parenteral nutrition dependence by promoting intestinal mucosal growth.

Semaglutide

A once-weekly GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management.

Liraglutide

The first once-daily GLP-1 analog to be FDA-approved for both type 2 diabetes (Victoza) and chronic weight management (Saxenda).

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.